HBeAg/HBeAb双阳性慢性乙型肝炎患者血清HBV RNA的变化及临床转归分析
Changes and Clinical Outcome of Serum HBV RNA in Patients with HBeAg/HBeAb Double Positive Chronic Hepatitis B
杨娟 1黄敏2
作者信息
- 1. 重庆三峡医药高等专科学校附属中医院,重庆 万州 404100
- 2. 重庆三峡医药高等专科学校附属人民医院,重庆 万州 404100
- 折叠
摘要
目的 探讨HBeAg/HBeAb双阳性慢性乙型肝炎(CHB)患者血清HBV RNA的变化及临床转归分析.方法 选取2020 年6 月至2022 年8 月诊治的102 例HBeAg/HBeAb双阳性CHB患者作为研究对象,设立为双阳组,同期选取51 例HBeAg阳性、HBeAb阴性的CHB患者和52 例HBeAg阴性、HBeAb阳性的CHB患者设立为对照1 组和对照2 组,对比血清HBV RNA变化.根据治疗方法不同将双阳组分为干扰素组(予以干扰素治疗,n=52)和恩替卡韦组(予以恩替卡韦治疗,n=50),对比 HBeAg、HBeAb 浓度及 HBeAg 转阴,HBeAb 仍阳性、HBeAg 和 HBeAb 同时转阴、HBeAg 未转阴,HBeAb仍阳性占比.结果 双阳组的HBV RNA水平均高于对照 1、2 组(P<0.05).治疗前,干扰素组和恩替卡韦组的HBeAg、HBeAb、HBV RNA比较,差异无统计学意义(P>0.05),治疗后,干扰素组的HBeAg、HBeAb、HBV RNA低于恩替卡韦组(P<0.05).干扰素组的HBeAg转阴,HBeAb仍阳性占比高于恩替卡韦组,而HBeAg未转阴,HBeAb仍阳性占比低于恩替卡韦组(P<0.05).2 组HBeAg和HBeAb同时转阴占比比较,差异无统计学意义(P>0.05).ROC曲线分析显示,HBV RNA预测CHB患者HBeAg/HBeAb双阳性和临床转归不良的AUC值分别为(0.936、0.954,P<0.05);敏感度分别为100.00%、93.10%;特异度分别为88.70%、76.70%.结论 HBV RNA在HBeAg/HBeAb双阳性CHB患者中呈高表达趋势,观察其水平变化有助于为预测临床转归提供指导.
Abstract
Objective To explore the changes of serum HBV RNA in patients with HBeAg/HBeAb double-positive chron-ic hepatitis B(CHB)and analyze the clinical outcome.Methods 102 patients with HBeAg/HBeAb double-positive CHB diag-nosed and treated from June 2020 to August 2022 were selected as the research object,and set as the double-positive group.At the same time,51 patients with HBeAg positive and HBeAb negative CHB and 52 patients with HBeAg negative and HBeAb positive CHB were selected as the control group 1 and the control group 2,and the changes of serum HBV RNA were compared.According to different treatment methods,the double-positive group was divided into interferon group(treated with interferon,n=52)and ente-cavir group(treated with entecavir,n=50).Compared the concentration of HBeAg and HBeAb and the conversion of HBeAg to negative,HBeAb remained positive,HBeAb and HBeAb turned negative at the same time,HBeAg did not turn negative and HBeAb was still positive.Results The level of HBV RNA in the double-positive group was higher than that in the control group 1 and 2(P<0.05).Before treatment,there was no significant difference in RNA levels of HBeAg,HBeAb and HBV between interferon group and entecavir group(P>0.05).After treatment,levels of HBeAg,HBeAb and HBV RNA in interferon group were lower than those in entecavir group(P<0.05).In interferon group,HBeAg turned negative,but HBeAg remained positive,the level of which was higher than that in entecavir group(P<0.05).There was no significant difference between the two groups in the proportion of HBeAg and HBeAb turning negative at the same time(P>0.05).ROC curve analysis showed that the AUC values of HBV RNA predicting HBeAg/HBeAb double positive and poor clinical outcome in CHB patients were(0.936,0.954,P<0.05).The sensitiv-ity was 100.00%and 93.10%respectively.The specificity was 88.70%and 76.70%respectively.Conclusion HBV RNA is highly expressed in patients with HBeAg/HBeAb double positive CHB,and observation of its level changes is helpful to predict the clinical outcome.
关键词
HBeAg/HBeAb双阳性/慢性乙型肝炎/HBV/RNA/临床转归Key words
HBeAg/HBeAb double positive/chronic hepatitis B/HBV RNA/clinical outcome引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据